Microglia play a central role in the control of brain inflammation. The phenotype of activated microglia varies depending on the pathology, from releasing toxins that harm adjacent cells, to decreasing the production of toxins and producing mediators that protect and repair adjacent cells. GPCRs expressed by microglia represent promising therapeutic targets to control the phenotype and function of these immune cells, ideally by favoring their healing responses and reducing their damaging potential. Our preliminary data suggest that microglia cell migration is modulated by a new adhesion GPCR, GPR125, that we found is activated by cannabinoid-like compounds. To study the pathophysiological role of these receptors, we developed JWH-451, an agonist that selectively activates GPR125 and found that it modulates the migration of both BV-2 cells and mouse microglia in primary culture. Here we propose to test the following hypothesis: Microglia function is regulated by cannabinoid-like compounds acting through GPR125, an adhesion GPCR. Selective agonists at GPR125 represent new pharmacological tools to study the involvement of microglia in controlling malignant astrocytoma pathogenesis. The following three aims will test this hypothesis:
AIM 1 : Identify the chemical determinants required for JWH-451 efficacy and selectivity at GPR125.
AIM 2 : How do GPR125 agonists regulate microglia cell function in vitro? AIM 3: How do GPR125 agonists regulate microglia cell function in vivo? The completion of this grant will increase our understanding of the molecular mechanism and cellular functions regulated by GPR125 in microglia. It will also provide new compounds that activate (and possibly antagonize) this receptor;pharmacological tools that have promising scientific and therapeutic value.
The goal of this RO1 is to characterize the molecular mechanisms and microglial cell functions regulated by GPR125, an adhesion GPCR expressed by microglia and involved in the control of brain inflammation. We will also test the therapeutic potential of GPR125 agonists in a mouse model of malignant astrocytomas.
|Häggström, Jenny; Cipriano, Mariateresa; Forshell, Linus Plym et al. (2014) Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray. Prostate 74:1107-17|
|Sexton, Michelle; Cudaback, Eiron; Abdullah, Rehab A et al. (2014) Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology 22:295-303|
|Stella, Nephi (2013) Chronic THC intake modifies fundamental cerebellar functions. J Clin Invest 123:3208-10|
|Sexton, Michelle; Silvestroni, Aurelio; Moller, Thomas et al. (2013) Differential migratory properties of monocytes isolated from human subjects naive and non-naive to Cannabis. Inflammopharmacology 21:253-9|
|Sexton, Michelle; Woodruff, Grace; Horne, Eric A et al. (2011) NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening. Chem Biol 18:563-8|
|Clark, Jeremy J; Sandberg, Stefan G; Wanat, Matthew J et al. (2010) Chronic microsensors for longitudinal, subsecond dopamine detection in behaving animals. Nat Methods 7:126-9|
|Marrs, William R; Blankman, Jacqueline L; Horne, Eric A et al. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13:951-7|
|Cudaback, Eiron; Marrs, William; Moeller, Thomas et al. (2010) The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One 5:e8702|
|Stella, Nephi (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017-30|
|Sexton, Michelle; Woodruff, Grace; Cudaback, Eiron et al. (2009) Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPO. PLoS One 4:e8271|
Showing the most recent 10 out of 26 publications